Quantification and distribution of <i>α</i><sub>1</sub>‐adrenoceptor subtype mRNAs in human vas deferens: comparison with those of epididymal and pelvic portions

Moriyama, Nobuo; Nasu, Kimio; Takeuchi, Takumi; Akiyama, Katsuyoshi; Murata, Satoshi; Nishimatsu, Hiroaki; Yano, Junichi; Tsujimoto, Gozoh; Kawabe, Kazuki

doi:10.1038/sj.bjp.0701485

Cited by 52 publications

(36 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is reported that alpha1A-AR is mainly expressed in the bladder neck, vas deferens, and seminal vesicles, and mediates human vas deferens contraction. 37,38 Therefore, this adverse effect may be explained by the high alpha1A-AR subtype selectivity of Silodosin.…”

Section: Discussionmentioning

confidence: 99%

The role of Silodosin as a new medical expulsive therapy for ureteral stones: a meta-analysis

et al. 2016

View full text Add to dashboard Cite

To evaluate the efficacy of Silodosin as a medical expulsive therapy of ureteral stones, we searched PubMed, EMBASE, the Cochrane Library, and CBM up to June 2015. All randomized controlled trials (RCTs) were identified in which patients were randomized to receive Silodosin versus placebo or other therapies for ureteral stones. Outcome measures assessed were overall stone expulsion rate (primary) and expulsion time, analgesics times, and the incidence of additional treatment and regarding treatment complications (secondary). Two authors independently assessed study quality and extracted data. All data were analyzed using RevMan 5.3. Seven RCTs with a total of 1035 patients met the inclusion criteria. The pooled meta-analysis showed a significant improvement in stone clearance with Silodosin (Silodosin versus placebo, OR ¼1.69, 95% CI [1.19-2.40], p ¼ 0.003; Silodosin versus tamsulosin, OR ¼2.82, 95% CI [1.79-4.44], p < 0.00001). According to the size and location of ureteral stone, the pooling effects of Silodosin were analyzed, with a meaningful expulsion rate in distal ureteral stone when the size was 5-10 mm. In addition, a shorter expulsion time, fewer analgesics times, and additional treatments were observed. The common side effect was retrograde ejaculation. In summary, Silodosin appears to be more effective than either placebo or tamsulosin. Within the limits of available data, highquality multicenter RCTs are needed to thoroughly evaluate the outcome in the future. ARTICLE HISTORY

show abstract

Section: Discussionmentioning

confidence: 99%

The role of Silodosin as a new medical expulsive therapy for ureteral stones: a meta-analysis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Song et al [22] reported that the overall incidence of ejaculatory dysfunction was 13.4% after 12 weeks of 0.2 mg tamsulosin treatment. Retrograde ejaculation is caused by smooth muscle relaxation in the prostate, urethra, bladder neck and vas deferens.…”

Section: Discussionmentioning

confidence: 99%

A Study on Efficacy and Safety of Silodosin in Geriatric Patients with Benign Prostatic Hyperplasia

Praneeth¹,

T.P²,

Bhandary³

et al. 2017

IOSR JDMS

View full text Add to dashboard Cite

“…The alpha 1A -AR is mainly expressed in the bladder neck, vas deferens and seminal vesicles. 23 Moreover, Moriyama et al 28 showed that the alpha 1A -AR subtype mediates human vas deferens contraction. Therefore, this adverse effect is explained by the high alpha 1A -AR subtype selectivity of silodosin.…”

Section: Wilt and Colleaguesmentioning

confidence: 99%

Silodosin is effective for treatment of LUTS in men with BPH: a systematic review

Ding¹,

Du²,

Hou³

et al. 2012

Asian J Androl

View full text Add to dashboard Cite

The aim of this study was to systematically review the evidence on the efficacy and safety of silodosin treatments on lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH) from randomized controlled trials. We searched PubMed (1966-December 2011), Embase (1974-December 2011 and the Cochrane Library Database (2011, Issue 12). The assessed outcome measures were the change from baseline for the International Prostate Symptom Score (IPSS), quality of life (QoL) score, peak urine maximum flow rate (Q max ), QoL related to urinary symptoms and adverse effects. Two authors independently assessed the study quality and extracted data. All data were analysed using RevMan 5.1. The meta-analysis included four randomized controlled trials with a total of 2504 patients. The study durations were each 12 weeks. At the follow-up end points, the pooled results showed that the change from baseline for the silodosin group was significantly higher than the placebo group for the IPSS, QoL score and Q max (mean difference (MD)522.78, P,0.00001; MD520.42, P50.004; MD51.17, P,0.00001,respectively) and patients felt more satisfied with QoL related to urinary symptoms in the silodosin group than the placebo group. Ejaculation disorder was the most commonly reported adverse effect. The pooled results also showed that the silodosin group was superior to the 0.2 mg tamsulosin group with respect to the IPSS and QoL score (IPSS: MD521.14, P50.02; QoL score: MD520.26, P50.02) and inferior to the 0.2 mg tamsulosin group with respect to Q max (MD520.85, P50.01). In contrast, there was no significant difference in the incidence of ejaculation disorder and dizziness between the silodosin and 0.2 mg tamsulosin groups. The current meta-analysis suggested that silodosin is an effective therapy for LUTS in men with BPH and is not inferior to 0.2 mg tamsulosin. Keywords: benign prostatic hyperplasia (BPH); KMD-3213; lower urinary tract symptoms (LUTS); silodosin; tamsulosin; systematic review; meta-analysis INTRODUCTION Histologically, benign prostatic hyperplasia (BPH) is a non-malignant enlargement of the prostate caused by cellular hyperplasia of both glandular and stromal elements.1 However, it is clinically characterised by lower urinary tract symptoms (LUTS) (urinary frequency, urgency, a weak and intermittent stream, the need to strain, a sense of incomplete emptying and nocturia), and can lead to complications, including acute urinary retention.2 The development of human BPH correlates with increasing age, 3 and LUTS are fairly common after the age of 50 years. 4 As is well known, the treatment options include alpha-blockers, five alpha-reductase inhibitors, transurethral resection of the prostate, transurethral microwave thermotherapy and herbal treatments (saw palmetto and b-sitosterol plant extracts). According to the EAU 2011 guidelines, alpha-blockers are currently the preferred first-line therapy for all men with moderate or severe LUTS/BPH.5 Alpha-blockers for BPH include alfuzosin, prazosin, doxazosin, tamsul...

show abstract

Quantification and distribution of α₁‐adrenoceptor subtype mRNAs in human vas deferens: comparison with those of epididymal and pelvic portions

Cited by 52 publications

References 20 publications

The role of Silodosin as a new medical expulsive therapy for ureteral stones: a meta-analysis

The role of Silodosin as a new medical expulsive therapy for ureteral stones: a meta-analysis

A Study on Efficacy and Safety of Silodosin in Geriatric Patients with Benign Prostatic Hyperplasia

Silodosin is effective for treatment of LUTS in men with BPH: a systematic review

Contact Info

Product

Resources

About

Quantification and distribution of α1‐adrenoceptor subtype mRNAs in human vas deferens: comparison with those of epididymal and pelvic portions

Cited by 52 publications

References 20 publications

The role of Silodosin as a new medical expulsive therapy for ureteral stones: a meta-analysis

The role of Silodosin as a new medical expulsive therapy for ureteral stones: a meta-analysis

A Study on Efficacy and Safety of Silodosin in Geriatric Patients with Benign Prostatic Hyperplasia

Silodosin is effective for treatment of LUTS in men with BPH: a systematic review

Contact Info

Product

Resources

About

Quantification and distribution of α₁‐adrenoceptor subtype mRNAs in human vas deferens: comparison with those of epididymal and pelvic portions